Explore

Trendline Trendline
Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal
Trendline Trendline
Sarepta Therapeutics Urges Caution in Expectations for Elevidys Recovery Amidst FDA Restrictions

Sarepta Therapeutics Urges Caution in Expectations for Elevidys Recovery Amidst FDA Restrictions

Sarepta Therapeutics Urges Caution in Expectations for Elevidys Recovery Amidst FDA Restrictions
Trendline Trendline
IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026
Trendline Trendline
DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke
Trendline Trendline
Angelini Pharma Acquires Catalyst Pharma for $4.1 Billion, Expanding into U.S. Market

Angelini Pharma Acquires Catalyst Pharma for $4.1 Billion, Expanding into U.S. Market

Angelini Pharma Acquires Catalyst Pharma for $4.1 Billion, Expanding into U.S. Market
Trendline Trendline
DiaMedica Therapeutics Reports Financial Results and Clinical Progress for Q1 2026

DiaMedica Therapeutics Reports Financial Results and Clinical Progress for Q1 2026

DiaMedica Therapeutics Reports Financial Results and Clinical Progress for Q1 2026
Trendline Trendline
Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline

LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline

LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline
Trendline Trendline
Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement